These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors. Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182 [TBL] [Abstract][Full Text] [Related]
3. Effects of combining rapamycin and resveratrol on apoptosis and growth of TSC2-deficient xenograft tumors. Alayev A; Salamon RS; Sun Y; Schwartz NS; Li C; Yu JJ; Holz MK Am J Respir Cell Mol Biol; 2015 Nov; 53(5):637-46. PubMed ID: 25844891 [TBL] [Abstract][Full Text] [Related]
4. Should mammalian target of rapamycin inhibitors be stopped in women with lymphangioleiomyomatosis awaiting lung transplantation? El-Chemaly S; Goldberg HJ; Glanville AR Expert Rev Respir Med; 2014 Dec; 8(6):657-60. PubMed ID: 25199529 [TBL] [Abstract][Full Text] [Related]
5. Characterization of cells cultured from chylous effusion from a patient with sporadic lymphangioleiomyomatosis. Grzegorek I; Zuba-Surma E; Chabowski M; Janczak D; Szuba A; Dziegiel P Anticancer Res; 2015 Jun; 35(6):3341-51. PubMed ID: 26026094 [TBL] [Abstract][Full Text] [Related]
6. Effect of beta-agonists on LAM progression and treatment. Le K; Steagall WK; Stylianou M; Pacheco-Rodriguez G; Darling TN; Vaughan M; Moss J Proc Natl Acad Sci U S A; 2018 Jan; 115(5):E944-E953. PubMed ID: 29339522 [TBL] [Abstract][Full Text] [Related]